SavedAdd your journal

Journals / The anatolian journal of family medicine (Online) / 2021 / Cilt: 4 - Sayı: 2

Sitagliptin Add-on to Metformin Plus Sulphonylurea Combination Therapy: The Efficacy of Triple Therapy on Metabolic and Glycemic Control in Type 2 Diabetes

Savaş Volkan KISIOĞLU
Özgür CAN
Sakin TEKİN
Mehmet SARGIN
Pages
165–169
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: Adding sitagliptin to the treatment is an effective and well-tolerated option in patients with type 2 diabetes who are not able to achieve adequate glycemic control despite metformin–sulphonylurea combi- nation treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: This study aimed to evaluate the efficacy of sitagliptin add-on metformin and sulphonylurea com- bination therapy in type 2 diabetic patients with insufficient glycemic control.
📊
Key Findings & Data:Methods: This study included who were treated with sitagliptin and continued with sitagliptin for 12 months while receiving metformin-sulphonylurea combination.
💡
Conclusion & Impact:Conclusion: Adding sitagliptin to the treatment is an effective and well-tolerated option in patients with type 2 diabetes who are not able to achieve adequate glycemic control despite metformin–sulphonylurea combi- nation treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Objectives: This study aimed to evaluate the efficacy of sitagliptin add-on metformin and sulphonylurea com- bination therapy in type 2 diabetic patients with insufficient glycemic control. Methods: This study included who were treated with sitagliptin and continued with sitagliptin for 12 months while receiving metformin-sulphonylurea combination. The fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) levels of the patients were measured at the initial, 3rd month, 6th month and 12th month. Results: A total of 40 patients were included in this study. The mean age patients was 59.2±9.6 years and initial HbA1c level was 7.6% (7.0-10.5). The HbA1c level of the patients was 6.8% (5.9-8.7) at 3 months, 6.7% (5.3–7.5) at 6 months, and 6.9% (5.4–9.1) at 12 months (p<0.001 for 0-3. months, p<0.001 for 0-6. months, p=0.003 for 0-12. months). Conclusion: Adding sitagliptin to the treatment is an effective and well-tolerated option in patients with type 2 diabetes who are not able to achieve adequate glycemic control despite metformin–sulphonylurea combi- nation treatment.

🔖

Cite This Article

KISIOĞLU, S. V., CAN, Ö., TEKİN, S., SARGIN, M. (2021). Sitagliptin Add-on to Metformin Plus Sulphonylurea Combination Therapy: The Efficacy of Triple Therapy on Metabolic and Glycemic Control in Type 2 Diabetes. The anatolian journal of family medicine (Online), Cilt: 4 - Sayı: 2, 165–169. https://ajindex.com/articles/365034

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (9)

  1. American Diabetes Association. Introduction: Standards of Medical Care in Diabetes—2019. Diabetes Care 2019;42(Sup- pl 1):1–2
  2. Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgar - den ZT, Bush MA, et al. Consensus statement by the american association of clinical endocrinologists and american college of endocrinology on the comprehensive type 2 diabetes man- agement algorithm - 2019 executive summary. Endocr Pract 2019;25(1):69–100
  3. Herman GA, Bergman A, Stevens C, Kotey P, Yi B, Zhao P, et al. Effect of single oral doses of sitagliptin, a dipeptidyl pep - tidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes. J Clin Endocrinol Metab 2006;91(11):4612–9
  4. Nauck MA, Kahle M, Baranov O, Deacon CF, Holst JJ. Addition of a dipeptidyl peptidase-4 inhibitor, sitagliptin, to ongoing therapy with the glucagon-like peptide-1 receptor agonist li- raglutide: A randomized controlled trial in patients with type 2 diabetes. Diabetes Obes Metab 2017;19(2):200–7
  5. Chen K, Kang D, Yu M, Zhang R, Zhang Y, Chen G, et al. Di- rect head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 inhibitors and sulphonylureas in pa- tients with type 2 diabetes mellitus: A meta-analysis of long- term randomized controlled trials. Diabetes Obes Metab 2018;20(4):1029–33
  6. Hermansen K, Kipnes M, Luo E, Fanurik D, Khatami H, Stein P; Sitagliptin Study 035 Group. Efficacy and safety of the dipep- tidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. Diabetes Obes Metab 2007;9(5):733–45
  7. Ba J, Han P, Yuan G, Mo Z, Pan C, Wu F, et al. Randomized trial assessing the safety and efficacy of sitagliptin in Chinese pa- tients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin. J Diabe - tes 2017;9(7):667–76
  8. Owens DR, Swallow R, Dugi KA, Woerle HJ. Efficacy and safety of linagliptin in persons with type 2 diabetes inadequately controlled by a combination of metformin and sulphonylurea: a 24-week randomized study. Diabet Med 2011;28(11):1352– 61
  9. Moses RG, Kalra S, Brook D, Sockler J, Monyak J, Visvanathan J, et al. A randomized controlled trial of the efficacy and safety of saxagliptin as add-on therapy in patients with type 2 dia- betes and inadequate glycaemic control on metformin plus a sulphonylurea. Diabetes Obes Meta